Although their businesses vary greatly, this year’s three finalists share good business sense and a keen eye for detail. The ...

The Dolphins are a mess and it’s only Week 1. There’s an adage about men when they reach their late-30s: They either get ...

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with ...

Swiss pharmaceutical and diagnostics giant Roche Holding has finally released some positive news about its oral breast cancer ...

ARS Pharmaceuticals (SPRY) shares real-world evidence evaluating the clinical performance of neffy in patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy.

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and ImmunologyAbout 9 ...

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDS ...

Cybin® is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet ...

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine ...

If you want the juiciest, most tender cuts of brisket every time, be sure to perform the bend test during the cooking process.

The Application of Enhanced Recovery after Surgery in Perioperative Nursing of Patients Undergoing Transoral Robotic Surgery ...

The CYB004-002 Phase 2 study is a randomized, double-blind study evaluating the safety and efficacy of CYB004 in participants with moderate to severe GAD (GAD-7 score ≥10) and are currently taking ...